高强度聚焦超声部分腺体消融治疗局限性前列腺癌的肿瘤学与功能学结局
该回顾性多中心系列分析了2013年1月至2017年9月接受Sonablate® 500系统部分腺体消融的局限性前列腺癌患者,共150例患者166次手术,89%为Grade Group≥2。平均随访24.3±14.4个月,PSA均值下降65%,高危患者确认活检中42%检出临床显著癌,24.6%接受挽救治疗,81%患者避免了全腺体治疗。
要点
- 部分腺体消融后81%患者避免全腺体治疗,严重并发症罕见。
- 高危复发患者确认活检中42%检出Grade Group≥2癌。
- 阳性针数多、肿瘤位于内侧或PSA较高者复发概率更高。
核心结论
- 高强度聚焦超声部分腺体消融治疗局限性前列腺癌安全且对功能结局影响轻微。
- 高危复发患者中局部复发和/或治疗失败发生于42%。
- 肿瘤位于内侧与更高失败率相关,严重并发症罕见。
研究设计与样本
- 回顾性多中心分析,纳入2013年1月至2017年9月接受部分腺体消融的患者。
- 共150例患者完成166次手术,使用Sonablate® 500系统。
- 纳入活检证实局限性病变且基于磁共振成像多灶性有限、倾向微创门诊治疗的患者。
- 89%病例为Grade Group 2或以上,平均随访24.3±14.4个月。
主要发现
- 前列腺特异抗原均值从7.9±6.8 ng/ml下降65%至最低点2.7±3.1 ng/ml。
- 87例(52%)高复发风险患者接受确认活检,37例(42%)检出临床显著癌(Grade Group 2或以上)。
- 37例(24.6%)接受挽救治疗,其中16例为重复部分腺体消融。
- 阳性针数更多、肿瘤位于内侧或前列腺特异抗原更高的患者复发概率更高。
- 81%患者避免了全腺体治疗。
临床怎么用
- 对于多灶性有限且倾向微创治疗的局限性前列腺癌患者,可考虑高强度聚焦超声部分腺体消融。
- 术后应对高复发风险患者进行确认活检以监测临床显著癌。
- 肿瘤位于内侧的患者应预期更高失败率并加强随访。
局限性
- 回顾性研究设计。
- 平均随访仅24.3±14.4个月。
- 确认活检仅在87例(52%)高复发风险患者中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the outcomes of high intensity focused ultrasound as primary treatment of localized prostate cancer in a retrospective series. This represents one of the largest published series of patients at intermediate and high risk. MATERIALS AND METHODS: We performed a retrospective multicenter analysis of patients who underwent partial gland ablation between January 2013 and September 2017. Patients with biopsy proven localized disease and limited multifocality based on magnetic resonance imaging who preferred minimally invasive outpatient therapy were treated with the Sonablate® 500 system. Oncologic and functional outcomes were analyzed as well as risk factors for recurrence. RESULTS: A total of 166 procedures were performed in 150 patients. Grade Group 2 or greater was present in 89% of cases. Mean ± SD followup was 24.3 ± 14.4 months. Mean prostate specific antigen decreased 65% from 7.9 ± 6.8 ng/ml to a nadir of 2.7 ± 3.1 ng/ml. Confirmatory biopsies were performed in 87 patients (52%) at high risk for recurrence. Clinically significant cancer (Grade Group 2 or greater) was detected in 37 cases (42%). Patients with a higher number of positive cores, a medial tumor location or higher prostate specific antigen had a higher probability of recurrence. Salvage treatment was done in 37 patients (24.6%), including 16 repeat partial gland ablation procedures. CONCLUSIONS: Partial gland ablation with high intensity focused ultrasound therapy was safe and it had a minimal impact on functional outcomes. Local recurrence and/or failure occurred in 42% of patients at high risk for recurrence. Medially located tumors were associated with a higher failure rate. Serious complications were rare. Whole gland treatment was avoided in 81% of patients.
引用
- Bass R, Fleshner N, Finelli A, et al. Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol. 2019. PMID: 30036514. doi:10.1016/j.juro.2018.07.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。